Adeno-associated virus (AAV) capsids are an effective mechanism for delivering gene therapies intended for therapeutic use. A critical production step is the separation of full capsids from empty ones ...
With an adeno-associated virus (AAV)-based product now licensed by the U.S. Food and Drug Administration for treatment of spinal muscular atrophy in newborns, the race is on to fully exploit AAV-based ...
Adeno-associated viruses (AAVs) are as small, replication-defective, non-enveloped viruses, serving as vectors for gene therapy. AAV vectors play a transformative role in delivering therapeutic genes ...
Many viral vectors have shown promise as gene delivery systems in small-animal studies 1. As these vectors progress to the next level of phase I and phase II clinical studies, it is important to ...
Adeno-associated viruses (AAVs) have emerged in recent years as a crucial tool in clinical gene therapies, offering low pathogenicity and long-lived gene expression in target cells. AAVs are simple ...
WALTHAM, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of ...
LOWER GWYNEDD, Pa.--(BUSINESS WIRE)--ChromaTan, a bioprocessing and biotools advanced biomanufacturing technology platform development company, is excited to announce the award of NIH IIB grant of $2M ...
Cobra Biologics, an international contract development, and manufacturing organization (CDMO) with a focus on advanced therapy medicinal products (ATMPs) has won a £1.5m shared grant from Innovate UK, ...
The main barrier in the progress of clinical gene therapy is the absence of a safe and efficient vector system with regulatable and tissue-specific characteristics. However, progress has been made in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results